In MLL-driven AML, elevated JMJD2C levels increase expression of pro-proliferative targets, among them Myc, Hoxa9, and Meis1 [12], while increased JMJD2C activity in JAK2V617F-positive HEL cells prevents cellular senescence [13]. This evidence concerns the gene KMT2A and acute myeloid leukemia.